DAVID MOES: Open Payments
NPI 1336697754 · CALABASH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,624 in 79 payments from 13 companies in 2025. Trend: 2023 $1,020 · 2024 $1,619 · 2025 $1,624
Food & beverage: $1,585Education: $39
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 22 | $567 |
| Otsuka America Pharmaceutical, Inc. | 15 | $248 |
| Janssen Pharmaceuticals, Inc | 10 | $214 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $188 |
| E.R. Squibb & Sons, L.L.C. | 6 | $106 |
| ABBVIE INC. | 5 | $86 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| Luye Pharma (USA) Ltd. | 2 | $36 |
| Alkermes, Inc. | 2 | $36 |
Products named: HETLIOZ, INVEGA SUSTENNA, FANAPT, CAPLYTA, REXULTI, COBENFY, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across NC — which companies pay providers there.
